Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|RET L629P RET D631_R635delinsG RET V637R||thyroid gland medullary carcinoma||predicted - sensitive||Pralsetinib||Case Reports/Case Series||Actionable||In a Phase I trial, a patient with medullary thryoid cancer harboring RET D631_R635delinsG, L629P, and V637R demonstrated a partial response, with maximal tumor reduction of 47% at 10 months, following treatment with Gavreto (pralsetinib) (PMID: 29657135; NCT03037385).||29657135|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|